Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

Molecular Signatures in Inflammatory Skin Disease (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Prof. Dr. Stephan Weidinger | Trial completion date: Dec 2028 ➔ Dec 2029 | Trial primary completion date: Dec 2027 ➔ Dec 2028

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Oncology • Psoriasis

Effectiveness of Tralokinumab for Upadacitinib-Refractory Atopic Dermatitis: 48-week Retrospective Study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study. (PubMed, Dermatitis) - " Tralokinumab is effective and well-tolerated in managing moderate-to-severe AD involving the H&N area, even in biologic-experienced patients. These findings support its use as a targeted therapy addressing both clinical and psychosocial burdens of H&N AD."

Journal • Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus

Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications. (PubMed, Pharmaceuticals (Basel)) - "Monoclonal antibodies targeting IgE (omalizumab) and IL-5 (mepolizumab, benralizumab, reslizumab, depemokimab) have demonstrated the ability to reduce exacerbation frequency and improve lung function, with newer agents such as depemokimab offering extended dosing intervals. Itepekimab, an anti-IL-33 antibody, effectively engages its target and mitigates tissue eosinophilia, while CM310-stapokibart, tralokinumab, and lebrikizumab inhibit IL-4/IL-13 signaling with variable efficacy depending on patient biomarkers. Comparative analyses of these biologics, encompassing affinity, dosing regimens, and trial outcomes, underscore the imperative of personalized therapy to optimize disease control in severe asthma."

Biomarker • Journal • Review • Asthma • Eosinophilia • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL13 • IL17A • IL33 • IL4 • IL5

Comparative Efficacy and Safety of Tralokinumab and Dupilumab in Moderate-to-Severe Atopic Dermatitis: A Narrative Review. (PubMed, J Clin Med) - "By highlighting these key distinctions, this review aims to support personalized treatment selection in AD. However, no direct head-to-head clinical trials have yet compared dupilumab and tralokinumab, and the available evidence is based on indirect comparisons from separate pivotal studies."

Journal • Review • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

Effectiveness of Dupilumab and Tralokinumab in Treating Nummular Eczema. (PubMed, Int J Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatology • Immunology

Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Clinically meaningful responses in both clinician-measured and patient-reported outcomes were observed in tralokinumab-treated (150 mg or 300 mg) adolescents who did not achieve IGA 0/1 at week 16 without rescue medication. Utilizing validated outcome measures of both efficacy and patient quality of life, alongside IGA scores, can enhance clinical decision-making regarding tralokinumab treatment responses in adolescents with moderate-to-severe AD."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy. (PubMed, Dermatitis) - "IgE, TARC, and LDH decreased throughout the 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy-naïve and -experienced patients, and the magnitudes of decreasing IgE and TARC or increasing TEC were higher in the latter. IgE, TARC, and LDH decreased during 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy- naïve and -experienced patients."

Biomarker • Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness of tralokinumab and lebrikizumab in Japanese atopic dermatitis patients with persistent head and neck dermatitis after long-term treatment with dupilumab: A single-centerretrospective study (EADV 2025) - No abstract available

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real world experience of switching from tralokinumab to lebrikizumab: Author's reply. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis. (PubMed, Dermatol Ther (Heidelb)) - "The availability of lebrikizumab as treatment for patients with severe AD would result in cost savings for Italy. Given the paucity of economic data on lebrikizumab, new economic studies should be conducted to confirm these findings."

HEOR • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Recalcitrant Atopic Dermatitis: Switch from Tralokinumab to Lebrikizumab (EADV 2025) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tacrolimus Ophthalmic Suspension Can Be an Effective Treatment Option for Biologic-Induced Refractory Conjunctivitis. (PubMed, Cureus) - "The disease is primarily driven by Th2-associated cytokines such as interleukin (IL)-4, IL-13, and IL-31, which contribute to inflammation and exacerbate pruritus, perpetuating the "itch-scratch cycle." Recently, biologics targeting Th2 cytokines - such as dupilumab, lebrikizumab, and tralokinumab - have emerged as effective treatment options for moderate-to-severe AD...Herein, we report a case of AD successfully controlled with lebrikizumab, in which the patient developed conjunctivitis refractory to artificial tears and fluorometholone eye drops. Switching to tacrolimus ophthalmic suspension resulted in marked improvement. While tacrolimus eye drops are not approved for conjunctivitis, they are indicated for vernal keratoconjunctivitis and may be considered in severe cases of AD-related conjunctivitis in consultation with ophthalmologists."

Journal • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • IL13

Rapid response and sustained remission of Hailey-Hailey disease under IL-13 inhibition with tralokinumab (EADV 2025) - No abstract available

Clinical • Genetic Disorders • IL13

Effect of tralokinumab on QoL in atopic patients with head and neck involvement (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Long-term efficacy with tralokinumab in patients with moderate-to-severe atopic dermatitis: final results from the 5-year ECZTEND study (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness and safety of 12-months tralokinumab treatment in 824 adults with atopic dermatitis: Final real-world data from the prospective, non-interventional, international, single-cohort TRACE study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness of 12-months tralokinumab treatment in 654 adults with atopic dermatitis with head & neck area involvement: Final real-world data from the prospective, non-interventional, international, single-cohort TRACE study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes (EADV 2025) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Patient-reported outcomes evaluations of 12-months tralokinumab treatment in 824 adults with atopic dermatitis: Real-world data from the prospective, non-interventional, international, single-cohort TRACE study (EADV 2025) - No abstract available

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-world use of tralokinumab: monotherapy versus overlapping treatment with conventional immunosuppressants in atopic dermatitis (EADV 2025) - No abstract available

Clinical • Monotherapy • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tralokinumab for Cronic Hand Eczema: 52-week experience and flexible dosing outcomes (EADV 2025) - No abstract available

Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: A Two-Year Multicenter Study (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Multicenter Study of 209 Patients with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab in a Real-World Practice. Efficacy and Safety Data at 52 Weeks (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tralokinumab therapy in head and neck atopic dermatitis: a case series of 18 patients (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology